xRead - An Update on Immunotherapy in Head and Neck Cancer (November 2025)

Clinical Review & Education Review

Immunotherapy in Head and Neck Squamous Cell Carcinoma

52 . Saito S, Shibata H, Adkins D, Uppaluri R. Neoadjuvant immunotherapy strategies in HPV-related head-and-neck cancer. Curr Otorhinolaryngol Rep . 2022;10(1):108-115. doi:10. 1007/s40136-021-00389-9 53 . Uppaluri R, Campbell KM, Egloff AM, et al. Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: a multicenter, phase II trial. Clin Cancer Res .2020; 26(19):5140-5152. doi:10.1158/1078-0432.CCR-20 1695 54 . Oliveira G, Egloff AM, Afeyan AB, et al. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. Sci Immunol . 2023;8(87):eadf4968. doi:10.1126/sciimmunol. adf4968 55 . Wise-Draper TM, Gulati S, Palackdharry S, et al. Phase II clinical trial of neoadjuvant and adjuvant pembrolizumab in resectable local-regionally advanced head and neck squamous cell carcinoma. Clin Cancer Res . 2022;28(7):1345-1352. doi:10.1158/ 1078-0432.CCR-21-3351 56 . Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. NEngl JMed . 2023;388(9):813-823. doi:10.1056/ NEJMoa2211437 57 . Vos JL, Elbers JBW, Krijgsman O, et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. NatCommun . 2021;12(1):7348. doi:10. 1038/s41467-021-26472-9 58 . Schoenfeld JD, Hanna GJ, Jo VY, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma: a phase 2 open-label randomized clinical trial. JAMAOncol . 2020;6(10):1563-1570. doi:10.1001/jamaoncol.2020.2955 59 . Hanna GJ, Dennis MJ, Scarfo N, et al. Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma. Clin CancerRes . 2024;30(15):3329-3336. doi:10.1158/ 1078-0432.CCR-24-0590 60 . Gavrielatou N, Doumas S, Economopoulou P, Foukas PG, Psyrri A. Biomarkers for immunotherapy response in head and neck cancer. Cancer Treat Rev . 2020;84:101977. doi:10.1016/j.ctrv.2020.101977 61 . Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature . 2017;541(7637):321-330. doi:10.1038/nature21349 62 . Ayers M, Lunceford J, Nebozhyn M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest .2017;127 (8):2930-2940. doi:10.1172/JCI91190 63 . Prat A, Navarro A, Paré L, et al. Immune-related gene expression profiling after PD-1 blockade in non–small cell lung carcinoma, head and neck squamous cell carcinoma, and melanoma. CancerRes .

42 . Wong DJ, Fayette J, Teixeira M, et al. Abstract CT009: IMvoke010: a phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). CancerRes . 2024;84(7)(suppl):CT009. doi:10.1158/1538-7445. AM2024-CT009 43 . Haddad RI, Ruscica D, Visa A, Li X, Licitra LF. eVOLVE-HNSCC: a global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT). J Clin Oncol . 2024;42(16)(suppl):TPS6120. doi:10.1200/JCO.2024. 42.16_suppl.TPS6120 44 . ClinicalTrials.gov. A trial evaluating the addition of nivolumab to cisplatin-RT for treatment of cancers of the head and neck (NIVOPOSTOP). Accessed September 10, 2024. https://clinicaltrials. gov/study/NCT03576417 45 . Zhang QE, Wu Q, Harari PM, Rosenthal DI. Randomized phase II/III confirmatory treatment selection design with a change of survival end points: statistical design of Radiation Therapy Oncology Group 1216. HeadNeck . 2019;41(1):37-45. doi:10.1002/hed.25359 46 . Uppaluri R, Lee NY, Westra W, et al. KEYNOTE-689: phase 3 study of adjuvant and neoadjuvant pembrolizumab combined with standard of care (SOC) in patients with resectable, locally advanced head and neck squamous cell carcinoma. J Clin Oncol . 2019;37(15)(suppl):TPS6090. doi:10.1200/JCO.2019.37.15_suppl.TPS6090 47 . Zech HB, Moeckelmann N, Boettcher A, et al. Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma. Future Oncol .2020;16 (36):3035-3043. doi:10.2217/fon-2020-0595 48 . ClinicalTrials.gov. Testing immunotherapy versus observation in patients with HPV throat cancer. Accessed September 10, 2024. https:// clinicaltrials.gov/study/NCT03811015 49 . Albiges L, Rodriguez LM, Kim SW, et al. Safety and clinical activity of MEDI5752, a PD-1/CTLA-4 bispecific checkpoint inhibitor, as monotherapy in patients (pts) with advanced renal cell carcinoma (RCC): preliminary results from an FTIH trial. JClin Oncol . 2022;40(16)(suppl):107. doi:10.1200/JCO. 2022.40.16_suppl.107 50 . Hanna GJ, Adkins DR, Zolkind P, Uppaluri R. Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. OralOncol . 2017;73:65-69. doi:10.1016/j.oraloncology.2017. 08.008 51 . Shibata H, Saito S, Uppaluri R. Immunotherapy for head and neck cancer: a paradigm shift from induction chemotherapy to neoadjuvant immunotherapy. Front Oncol . 2021;11:727433. doi:10.3389/fonc.2021.727433

2017;77(13):3540-3550. doi:10.1158/0008-5472. CAN-16-3556 64 . Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science .2018;362 (6411):eaar3593. doi:10.1126/science.aar3593 65 . Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol . 2020;20(1):25-39. doi:10.1038/s41577-019-0218-4 66 . Zhou X, Ni Y, Liang X, et al. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol . 2022;13:915094. doi:10.3389/ fimmu.2022.915094 67 . Pozniak J, Pedri D, Landeloos E, et al. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. Cell . 2024;187(1):166-183.e25. doi:10.1016/j.cell.2023. 11.037 68 . Zhang W, Liang Z, Zhao Y, et al. Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials. Front Immunol . 2024;15:1359302. doi:10.3389/ fimmu.2024.1359302 69 . Wu D, Li Y, Xu P, et al. Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. NatCommun . 2024;15(1): 2177. doi:10.1038/s41467-024-46444-z 70 . Oweida AJ, Darragh L, Phan A, et al. STAT3 modulation of regulatory T cells in response to radiation therapy in head and neck cancer. JNatl Cancer Inst . 2019;111(12):1339-1349. doi:10.1093/ jnci/djz036 71 . Darragh LB, Knitz MM, Hu J, et al. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC. NatCancer . 2022;3(11):1300-1317. doi:10.1038/s43018-022 00450-6 72 . Leidner R, Crittenden M, Young K, et al. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. J Immunother Cancer . 2021;9(5):e002485. doi:10.1136/jitc-2021-002485 73 . Yang Y, Wang SX, Lei YM, Mao YP. Induction chemoimmunotherapy followed by radiotherapy in locally advanced head and neck squamous cell carcinoma: a real-world study. J Clin Oncol .2024;42 (23)(suppl):131. doi:10.1200/JCO.2024.42.23_suppl.131 74 . Hanna GJ, Haddad RI, Lorch JH. Induction chemotherapy for locoregionally advanced head and neck cancer: past, present, future? Oncologist . 2013;18(3):288-293. doi:10.1634/theoncologist. 2012-0286

528 JAMA Otolaryngology–Head & Neck Surgery May 2025 Volume 151, Number 5 (Reprinted)

jamaotolaryngology.com

© 2025 American Medical Association. All rights reserved, including those for text and data mining, AI training, and similar technologies.

Downloaded from jamanetwork.com by Icahn School of Medicine at Mount Sinai user on 09/02/2025